Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives


 12th October 2009
Lonza AG

Lonza and BioWa Introduce Potent New Cell Line for Recombinant Antibody Production Basel, Switzerland and Princeton, NJ, USA, 12 October 2009 – Lonza and BioWa, Inc today unveiled POTELLIGENT® CHOK1SV, a new host cell line for manufacturing recombinant antibodies. The new cell line combines the power of BioWa’s engineered glycosylation POTELLIGENT® Technology with the advantages of Lonza’s proprietary GS Gene Expression System™ and industry-leading cell line CHOK1SV.

“Combining these leading-edge technologies takes the GS System™ to the next level and offers customers the latest innovation for efficient production of therapeutic proteins. The advantages of the POTELLIGENT® CHOK1SV cell line -- high productivity and antibody potency -- have the potential to significantly reduce the cost of goods for an antibody-based medicine,” said Dr. Stephan Kutzer, COO of Lonza Biopharmaceuticals.

“The new POTELLIGENT® CHOK1SV cell line leverages an already widely practiced technology”, said Dr. Masamichi Koike, President and CEO of BioWa. “We are pleased with both the success of our strategic collaboration with Lonza and the promise of this new cell line to become a standard in biological drug development programs.”


• The POTELLIGENT® CHOK1SV cell line retains the desirable features of a high-productivity cell line (robust, high-yielding, scalable)

• Proven bioprocess platform for CHOK1SV is repeatable in the new cell line

• Antibodies produced by the new cell line: o Exhibit enhanced antibody dependent cellular cytotoxicity (ADCC) even with the low-ADCC allotype of CD16, overcoming CD16 polymorphism o Can exert potent cytotoxic effects when their target antigen is low o Work in whole blood o Retain all the other desirable features of antibodies, such as Protein A binding. The POTELLIGENT® CHOK1SV cell line is now available as one of the options in Lonza cell line construction offerings with packages available for existing GS System™ license holders and new customers. To learn more about the benefits of POTELLIGENT® CHOK1SV, please contact one of our experts at +44 (0) 1753 777 000 or

About the GS Gene Expression System™ The GS Gene Expression System™, which is owned and licensed by Lonza, is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Nearly 100 biotechnology and pharmaceutical companies and over 75 academic laboratories worldwide are successfully using the GS Gene Expression System™ which has established itself as the industry standard. This system is characterized by its speed and ease of use. In addition, the higher yielding cell lines provide cost-efficient production of therapeutic proteins.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at

About POTELLIGENT® Technology

POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. Over a dozen leading biopharmaceutical companies practice the POTELLIGENT® Technology under license from BioWa. A growing number of POTELLIGENT® antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab® platform. AccretaMab® platform consists of POTELLIGENT® and COMPLEGENT® Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT® and COMPLEGENT® Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at

POTELLIGENT®, COMPLEGENT®, and AccretaMab® are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.


Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |